Precigen posted PAPZIMEOS net revenue of $53.1 million in Q2, more than double the prior quarter and delivering a net income of $20.1 million. The earnings boost underscores the product’s rapid market adoption and gives the company cash‑flow runway to reach break‑even by year‑end, appealing to growth‑focused investors.
Key Highlights
- Price $7.10 (+8.7% today) · Mkt cap $2.3B · PAPZIMEOS revenue $53.1M · Next catalyst: Aug 4 conference call
- Net income $20.1M driven by PAPZIMEOS sales
- Short interest 11% of shares outstanding, covering 9.6 days of average volume
- FDA granted seven‑year exclusivity and permanent J‑code for PAPZIMEOS
Precigen (NASDAQ: PGEN) reported PAPZIMEOS net revenue of $53.1 million for the quarter ended June 30, 2026, more than double the prior quarter and enough to generate a net income of $20.1 million, or $0.05 per share. The company said the rapid uptake of PAPZIMEOS, backed by a permanent J‑code and coverage of roughly 315 million US lives, supports the earnings uplift and positions the firm for cash‑flow break‑even by the close of 2026. Investors will watch how this profitability foundation translates into sustained growth as the firm expands internationally.
By the Numbers
PAPZIMEOS revenue of $53.1 million dwarfed the $3.9 million recorded for the same period a year earlier and eclipsed the $55.0 million prior‑year total revenue, illustrating a sharp turnaround. Cash, cash equivalents and investments stood at $38.7 million, providing a buffer to fund ongoing trials and global rollout. R&D expenses fell by $4.2 million while SG&A grew by $6.1 million, reflecting a shift toward commercial scaling.
The net income of $20.1 million contrasts with a prior‑year loss of $26.6 million, evidencing a swing to profitability that could improve valuation multiples. This earnings profile suggests the firm may attract financing on more favorable terms as cash reserves strengthen.
Segment Detail
The PAPZIMEOS launch benefited from 100 % field engagement, intensive patient and provider campaigns, and a permanent J‑code (J3404) assigned by Medicaid Services, enabling coverage of approximately 315 million insured Americans. A position paper from the Recurrent Respiratory Papillomatosis Foundation and 16 leading physicians now endorses PAPZIMEOS as first‑line therapy for adult RRP, reinforcing market acceptance. Enrollment exceeded 500 adults across major centers, while an open‑label redosing study (NCT06538480) continues, supporting future revenue streams.
European regulators are reviewing a marketing authorization, and orphan drug status has been granted, opening pathways for overseas expansion. Such broad endorsement and regulatory footing suggest the product could dominate the RRP niche, limiting competitive threats.
Guidance
Management indicated the $38.7 million cash position is sufficient to sustain operations through year‑end, targeting cash‑flow break‑even by that time. The company plans to leverage FDA’s seven‑year exclusivity to fund pediatric studies and pursue global market entry, a strategy that could expand the addressable pool beyond the United States. Ongoing Phase 2 trials for PRGN‑2009 under a CRADA with the National Cancer Institute aim to diversify the pipeline into HPV‑associated cancers, presenting a potential new revenue source.
If these trials meet milestones, the firm could see incremental earnings that complement the core PAPZIMEOS business, reducing reliance on a single product line.
Market Reaction
Shares jumped 8.7 % to $7.10 in pre‑market trading, extending a 52.6 % year‑to‑date gain and a 16.6 % rise over the past month, while the 52‑week range sits between $1.70 and $6.80. The stock outperformed sector peers, with RARE up 6.4 %, CDNA up 0.5 % and VCEL down 1.1 % on the same day. Short interest remains at 11 % of shares outstanding, representing 9.6 days of average volume, indicating moderate bearish positioning.
The price move reflects optimism around the profitability swing and the upcoming August 4 conference call, where management will likely discuss further commercialization plans.
Peers Moving on This News
- Ultragenyx Pharmaceutical Inc (RARE) up 6.4%
- CareDx Inc (CDNA) up 0.5%
- Vericel Corp (VCEL) down 1.1%
Analysis based on company disclosures and public reporting; figures verified against the source and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...